Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations

16 Oct 2017

Abstract excerpt

INTRODUCTION: The bromodomain and extra-terminal (BET) family of proteins are epigenetic readers of acetylated histones regulating a vast network of protein expression across many different cancers. Therapeutic targeting of BET is an attractive area of clinical development for metastatic castration-resistant prostate cancer (mCRPC), particularly due to its putative effect on c-MYC expression and its interaction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29032717
DOI: 10.1080/13543784.2017.1393518

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsPMID 29032717Read ↗

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerSemantic proximity Read ↗

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerSemantic proximity Read ↗

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancerSemantic proximity Read ↗

The Silver Lining in BET Protein Targeting for Advanced Prostate Cancer Pharmacotherapy: Recent UpdatesSemantic proximity Read ↗

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Semantic proximity Read ↗

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerSemantic proximity Read ↗

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerSemantic proximity Read ↗

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate CancerSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.Semantic proximity Read ↗

BET inhibitors as novel therapeutic agents in breast cancerSemantic proximity Read ↗

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.